Jazz Pharmaceuticals plc Price Chart
Jazz Pharmaceuticals plc JAZZN.MX Financial and Trading Overview
Jazz Pharmaceuticals plc stock price | 2027.24 MXN |
Previous Close | 2830 MXN |
Open | 0 MXN |
Bid | 0 MXN x N/A |
Ask | 0 MXN x N/A |
Day's Range | 2830 - 2830 MXN |
52 Week Range | 2830 - 2830 MXN |
Volume | 0 MXN |
Avg. Volume | N/A |
Market Cap | N/A |
Beta (5Y Monthly) | 0.745601 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -149.42 MXN |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
JAZZN.MX Valuation Measures
Enterprise Value | 185.78B MXN |
Trailing P/E | N/A |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 54.296734 |
Enterprise Value/Revenue | 49.693 |
Enterprise Value/EBITDA | 110.667 |
Trading Information
Jazz Pharmaceuticals plc Stock Price History
Beta (5Y Monthly) | 0.745601 |
52-Week Change | N/A |
S&P500 52-Week Change | 19.24% |
52 Week High | 2830 MXN |
52 Week Low | 2830 MXN |
50-Day Moving Average | N/A |
200-Day Moving Average | N/A |
JAZZN.MX Share Statistics
Avg. Volume (3 month) | N/A |
Avg. Daily Volume (10-Days) | N/A |
Shares Outstanding | N/A |
Float | 62.37M |
Short Ratio | N/A |
% Held by Insiders | 2.59% |
% Held by Institutions | 93.06% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -4.18% |
Operating Margin (ttm) | 28.66% |
Gross Margin | 92.40% |
EBITDA Margin | 44.90% |
Management Effectiveness
Return on Assets (ttm) | 5.87% |
Return on Equity (ttm) | -4.50% |
Income Statement
Revenue (ttm) | 3.74B MXN |
Revenue Per Share (ttm) | 59.39 MXN |
Quarterly Revenue Growth (yoy) | 9.70% |
Gross Profit (ttm) | 3.39B MXN |
EBITDA | 1.68B MXN |
Net Income Avi to Common (ttm) | -156287008 MXN |
Diluted EPS (ttm) | -149.42 |
Quarterly Earnings Growth (yoy) | 4114.89% |
Balance Sheet
Total Cash (mrq) | 1.17B MXN |
Total Cash Per Share (mrq) | 18.25 MXN |
Total Debt (mrq) | 5.81B MXN |
Total Debt/Equity (mrq) | 174.21 MXN |
Current Ratio (mrq) | 3.064 |
Book Value Per Share (mrq) | 52.121 |
Cash Flow Statement
Operating Cash Flow (ttm) | 1.38B MXN |
Levered Free Cash Flow (ttm) | 1.42B MXN |
Profile of Jazz Pharmaceuticals plc
Country | Mexico |
State | N/A |
City | Dublin |
Address | Waterloo Exchange |
ZIP | 4 |
Phone | 353 1 634 7800 |
Website | https://www.jazzpharma.com |
Industry | |
Sector(s) | |
Full Time Employees | 2800 |
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.
Q&A For Jazz Pharmaceuticals plc Stock
What is a current JAZZN.MX stock price?
Jazz Pharmaceuticals plc JAZZN.MX stock price today per share is 2027.24 MXN.
How to purchase Jazz Pharmaceuticals plc stock?
You can buy JAZZN.MX shares on the Mexico exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Jazz Pharmaceuticals plc?
The stock symbol or ticker of Jazz Pharmaceuticals plc is JAZZN.MX.
How many shares does Jazz Pharmaceuticals plc have in circulation?
The max supply of Jazz Pharmaceuticals plc shares is 0.
What is Jazz Pharmaceuticals plc Price to Earnings Ratio (PE Ratio)?
Jazz Pharmaceuticals plc PE Ratio is now.
What was Jazz Pharmaceuticals plc earnings per share over the trailing 12 months (TTM)?
Jazz Pharmaceuticals plc EPS is -149.42 MXN over the trailing 12 months.